Increased Spleen Volume in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab in Comparison to Lenvatinib: A Retrospective Analysis

Hatanaka, Takeshi; Naganuma, Atsushi; Furusawa, Ai; Tamura, Yukie; Suzuki, Yuhei; Hoshino, Takashi; Yata, Yutaka; Uraoka, Toshio; Kakizaki, Satoru

doi:10.1159/000528081

Cited by 3 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, we calculated the albumin-bilirubin (ALBI) score [16] and classified the patients into four groups according to the modified ALBI (mALBI) grade (grades 1, 2a, 2b, and 3) [17]. The ALBI score and mALBI grade were calculated as follows [16][17][18]: ALBI score = (log 10 bilirubin (µmol/L) × 0.66) − (serum albumin (g/L) × 0.085) mALBI grade: Grade 1 (ALBI score ≤ −2.60); Grade 2a (ALBI score > −2.60 to −2.27); Grade 2b (ALBI score > −2.27 to −1.39); Grade 3 (ALBI score > −1.39).…”

Section: Determination Of Data Related To the Hepatic Function Reserv...mentioning

confidence: 99%

A Low Geriatric Nutritional Risk Index Is Associated with Low Muscle Volume and a Poor Prognosis among Cirrhotic Patients

Enomoto,

Yuri,

Nishimura

et al. 2023

Medicina

View full text Add to dashboard Cite

Background and Objectives: The geriatric nutritional risk index (GNRI) is an easily calculable index that can be determined using three common clinical variables. The GNRI is suggested to be related to sarcopenia in cirrhotic patients. However, the relationship between the GNRI and the prognosis in patients with liver cirrhosis (LC) has not been reported. The aim of the present research is to study the association of the GNRI with the nutritional status, hepatic function reserve, and prognosis in patients with liver cirrhosis (LC). Materials and Methods: A total of 370 cirrhotic patients whose nutritional statuses were evaluated using anthropometric measurements and bioimpedance analysis were studied. The associations between the GNRI and nutritional status and the GNRI and hepatic function reserve were analyzed. We also investigated the GNRI and prognosis of patients with LC. Results: The median age of the enrolled patients was 66 years old, and 266 (71.9%) patients had viral hepatitis-related LC. The GNRI was shown to decrease with the progression of chronic liver disease, represented by an increased FIB-4 index and severe Child–Pugh and mALBI grades. In addition, a low GNRI (<92) was associated with severe cirrhosis-related metabolic disorders, including a low branched-chain amino acid-to-tyrosine ratio (BTR) and a low zinc value. The GNRI was positively correlated with two nutrition-related anthropometric variables (% arm circumference and % arm muscle circumference), and a low GNRI was related to a low skeletal muscle mass index (SMI) (<7.0 kg/m2 for men or <5.7 kg/m2 for women), as determined by using bioimpedance analysis. In addition, patients with a low GNRI (<92) had a poorer prognosis than those with a high GNRI (≥92) (log-rank test: p = 0.0161, and generalized Wilcoxon test, p = 0.01261). Conclusions: Our results suggest that a low GNRI is related to severe chronic liver disease, low muscle volume, and a poor prognosis of patients with cirrhosis.

show abstract

Section: Determination Of Data Related To the Hepatic Function Reserv...mentioning

confidence: 99%

A Low Geriatric Nutritional Risk Index Is Associated with Low Muscle Volume and a Poor Prognosis among Cirrhotic Patients

Enomoto,

Yuri,

Nishimura

et al. 2023

Medicina

View full text Add to dashboard Cite

show abstract

Factors Affecting an Increase in Spleen Volume and Association of Spleen Volume Variation with the Clinical Outcomes of Atezolizumab and Bevacizumab Treatment for Hepatocellular Carcinoma: A Retrospective Analysis

Hatanaka,

Saito,

Kakizaki

et al. 2024

Oncology

View full text Add to dashboard Cite

Introduction: Gastrointestinal varices rupture is considered to be prone to occur during atezolizumab and bevacizumab (Atez/Bev) treatment. This study aimed to investigate predictive factors affecting the increase in spleen volume (SpV) and the association of SpV variation with the clinical outcomes of Atez/Bev. Methods: A total of 164 HCC patients were included in this retrospective multicenter study. We measured SpV based on CT scans obtained before treatment and at evaluations. We used the inverse probability of treatment weight to address the imbalance between patient characteristics. Results: The median pretreatment SpV was 184 (130–257) cm3 and the median SpV variation was 27 (9–60) cm3. An increase in the SpV was observed in 140 patients (85.4%). Age <74 years (p = 0.03), mALBI grade 2b or 3 (p = 0.03), and pretreatment SpV ≥184 cm3 (p < 0.001) were significantly associated with increased SpV. There were no significant differences in progression-free survival (PFS) or overall survival (OS) between patients with SpV variation <25 cm3 and those with SpV variation ≥25 cm3 in the crude (p = 0.3 and 0.7) and IPTW-weighted cohorts (p = 0.08 and 0.8, respectively). Regarding pretreatment SpV, there were no significant differences in PFS or OS between patients with and without pretreatment spleen enlargement in the crude (both p = 0.3) and IPTW-weighted cohort (p = 0.6 and 0.3, respectively). Conclusion: Caution is warranted to detect the aggravation of portal hypertension when administering Atez/Bev to young patients or patients with an impaired liver function or pretreatment spleen enlargement. The impact of spleen modulation by Atez/Bev appears to be limited on clinical efficacy.

show abstract

Research Status and New Trends of Hepatocellular Carcinoma with Pulmonary Metastasis (Preprint)

Zhang¹,

Dang²,

Yang³

et al. 2023

Preprint

View full text Add to dashboard Cite

BACKGROUND Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. HCC recurrence and metastasis (most of which are pulmonary metastases ) are the main causes of death in patients. This study aimed to construct a model to analyze and evaluate the relationship between HHC and scientific publications in lung metastatic tumors. OBJECTIVE Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. HCC recurrence and metastasis (most of which are pulmonary metastases ) are the main causes of death in patients. This study aimed to construct a model to analyze and evaluate the relationship between HHC and scientific publications in lung metastatic tumors. METHODS Collect original research articles related to hepatocellular carcinoma and pulmonary metastases published in the Web of Science Core Collection database before January 5, 2023. Understand the development status of the field of hepatocellular carcinoma and pulmonary metastases through co-authored scientific knowledge maps of countries/regions, institutions and authors, and analyze the subject through co-occurrence keyword maps, co-cited author maps, and distribution of highly cited papers Research hotspots in the field, analyze the research frontiers of the subject field through the co-occurrence keyword frequency and emergence analysis map, and explore the global development trend of the subject field through the co-cited reference map. RESULTS A total of 971 articles related to HCC and lung metastasis were included. Both the number of articles published and the frequency of citations have increased significantly over the past five years. The countries/regions, institutions, scholars and journals with the largest number of published articles are China, Fudan Univ, Tang ZY (Zhongshan Hosp, Key Lab Carcinogenesis & Canc Invas, Liver Canc Inst, Fudan Univ) and Hepatology. The countries/regions, institutions, scholars and journals with the most influential published articles are USA, Fudan Univ, Fan J (Zhongshan Hosp, Key Lab Carcinogenesis & Canc Invas, Liver Canc Inst, Fudan Univ) and Am J Clin Pathol. Mol Cancer is the most Effective Journal. The top five co-occurrence keywords are hepatocellular carcinoma, expression, cancer, cell and invasion. The current research frontiers are promote，hepatocellular carcinoma (HCC) and suppresse. CONCLUSIONS Chinese scholars and research institutions have absolute academic leadership in the field of HCC and lung metastatic tumor research. The results of this quantitative study can provide a reference for government departments to formulate/modify health policies or measures. At the same time, this research can also help relevant scholars accurately identify research hotspots and frontiers in the research of HCC and lung metastatic tumors, and play an important guiding role in subsequent research.

show abstract

Increased Spleen Volume in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab in Comparison to Lenvatinib: A Retrospective Analysis

Cited by 3 publications

References 24 publications

A Low Geriatric Nutritional Risk Index Is Associated with Low Muscle Volume and a Poor Prognosis among Cirrhotic Patients

A Low Geriatric Nutritional Risk Index Is Associated with Low Muscle Volume and a Poor Prognosis among Cirrhotic Patients

Factors Affecting an Increase in Spleen Volume and Association of Spleen Volume Variation with the Clinical Outcomes of Atezolizumab and Bevacizumab Treatment for Hepatocellular Carcinoma: A Retrospective Analysis

Research Status and New Trends of Hepatocellular Carcinoma with Pulmonary Metastasis (Preprint)

Contact Info

Product

Resources

About